Effects of a 12-Week Waltz Dance Intervention on Cardiovascular Health in Women Aged 45-65 With Dyslipidemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Waltz Dance.
- Who it may be relevant to
- Registry conditions: Dyslipidemia, Cardiopulmonary Fitness. Basic parameters: 45 years — 65 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of a 12-Week Waltz Dance Intervention on Cardiovascular Health in Women Aged 45-65 With Dyslipidemia: A Randomized Controlled Trial
Overview
The goal of this clinical trial is to learn whether Waltz dance can improve cardiometabolic and bone health in sedentary women aged 45-65 with abnormal lipid levels. The main questions it aims to answer are: Can Waltz dance improve blood lipid profiles, including total cholesterol, triglycerides, HDL-C, and LDL-C? Can it improve body composition, cardiorespiratory fitness, vascular function, and bone mineral density? Researchers will compare a Waltz dance group with a control group that maintains their usual lifestyle to see if the dance intervention leads to better health outcomes. Participants will: Attend supervised Waltz dance classes three times a week for 12 weeks, each session lasting 105 minutes. Complete physical tests and blood draws before and after the program to measure changes in lipid levels, body composition, fitness, and bone density. Wear an accelerometer to monitor energy expenditure and physical activity during the program.
Interventions
- Behavioral Waltz Dance
Participants in this arm will receive a structured Waltz dance intervention as moderate-intensity aerobic exercise. The program consists of 3 supervised sessions per week for 12 weeks, each lasting 105 minutes. Each session includes a 5-minute warm-up, 50 minutes of solo and partner Waltz practice, a 5-minute rest, 40 minutes of choreographed combinations, and a 5-minute cool-down. The dance routines are progressive and designed to improve cardiovascular fitness, coordination, and balance. Exerc
Primary outcome measures
- Total Cholesterol (TC) Level [Time frame: From enrollment to the end of treatment at 12 weeks]
- Triglycerides (TG) Level [Time frame: From enrollment to the end of treatment at 12 weeks]
- High-Density Lipoprotein Cholesterol (HDL-C) Level [Time frame: From enrollment to the end of treatment at 12 weeks]
- Low-Density Lipoprotein Cholesterol (LDL-C) Level [Time frame: From enrollment to the end of treatment at 12 weeks]
Secondary outcome measures (5)
- Systolic and Diastolic Blood Pressure and Pulse Pressure (mmHg) [Time frame: From enrollment to the end of treatment at 12 weeks]
- Pulse Wave Velocity (m/s) [Time frame: From enrollment to the end of treatment at 12 weeks]
- Ankle-Brachial Index (ABI) [Time frame: From enrollment to the end of treatment at 12 weeks]
- Cardiorespiratory Fitness - Maximal Oxygen Uptake (VO2max) [Time frame: From enrollment to the end of treatment at 12 weeks]
- Peak Exercise Heart Rate (bpm) [Time frame: From enrollment to the end of treatment at 12 weeks]
Eligibility criteria
Inclusion criteria
- Female participants aged between 45 and 65 years.
- Diagnosed with dyslipidemia (based on clinical lipid profile: TC ≥ 6.2 mmol/L, TG ≥ 2.3 mmol/L, LDL-C ≥ 4.1 mmol/L, or HDL-C < 1.0 mmol/L).
- Sedentary lifestyle (less than 60 minutes of structured physical activity per week in the last 6 months).
- Able to participate safely in moderate-intensity exercise as confirmed by a medical evaluation.
- Willing to participate in a 12-week supervised exercise program, 3 times per week.
- Able to understand study procedures and provide written informed consent.
Exclusion criteria
- Diagnosis of cardiovascular disease requiring medical supervision during exercise (e.g., unstable angina, recent myocardial infarction).
- Severe musculoskeletal disorders (e.g., advanced osteoarthritis, recent fractures) limiting mobility or physical activity.
- Neurological or cognitive disorders affecting motor function or communication.
- Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg at rest).
- Diagnosed osteoporosis with high fracture risk (T-score ≤ -2.5 and history of fragility fractures).
- Any endocrine disorder that significantly affects lipid metabolism (e.g., uncontrolled thyroid disease, Cushing's syndrome).
- Participation in structured exercise or dance programs within the past 12 months.
- Current use of medications significantly affecting lipid levels (e.g., high-dose statins) unless dose has been stable for at least 3 months.
- Any condition judged by the investigator to interfere with safe participation in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07061249 · AWFiS/2025_5_JL